Data Safety Monitoring Board gives approval for ongoing retinitis pigmentosa clinical trial to progress into Phase II element based on short term safety data
8 November 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today provides an update regarding the Company’s ongoing Phase I/II clinical trial of its hRPC cell therapy candidate for the blindness-causing disease, retinitis pigmentosa (“RP”).